ArticleAnalytical and bioanalytical chemistry2025
Analysis of metabolites and metabolic pathways of troponin activator in rats using UHPLC-MS.
Article in Analytical and bioanalytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Annual Banned-Substance Review 18th Edition-Analytical Approaches in Human Sports Drug Testing 2024/2025.Drug testing and analysis · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Troponin activators, including Reldesemtiv and Tirasemtiv, represent a class of drugs that enhance the contractility of cardiac muscle and delay the onset of muscle fatigue. Consequently, they were classified as prohibited substances by the World Anti-Doping Agency (WADA) in 2024. This study aimed to develop an ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS)-based method to quantify Reldesemtiv and Tirasemtiv levels in rat urine, blood, and feces over a 72-h period following transgastric administration. Additionally, Compound Discoverer 3.3 was utilized to investigate the metabolites and metabolic pathways of these two drugs in vivo. Twelve metabolites of Reldesemtiv and seven metabolites of Tirasemtiv were identified. Notably, ten of the twelve Reldesemtiv metabolites had not been previously reported in the literature. Using UHPLC-MS, the concentration of each metabolite in urine and blood was measured at various time points, enabling the generation of a metabolic profile. Six metabolites of Reldesemtiv are detectable 72 h after administration, while Tirasemtiv and its metabolite T-M1a were also detectable at the same time point. This analytical method can characterize the metabolic profiles of the drugs and their metabolites, as well as identify unknown and long-lived metabolites in drug testing. These capabilities are critical for the quantitative analysis of troponin activators within complex biological matrices, supporting their study in physiological and doping-control contexts.
Indexed as
Identifiers
40739458What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.